SCNI
SCINAI Ends PC111 Arrangements to Refocus on NanoAb and CDMO Work
Scinai says it has concluded its PC111 arrangements and will redirect capital to its NanoAb platform and expanding CDMO business.
SCNI
Market-moving news on Scinai Immunotherapeutics (NASDAQ: SCNI): filings, earnings, deals and other events, from REDFILED.